Table 2 Number of completed trials registered on ClinicalTrials.gov, of which results have been published on ClinicalTrials.gov or in the academic literature. Percentages are displayed as a proportion of all completed trials
From: Missing clinical trial data: the evidence gap in primary data for potential COVID-19 drugs
Generic name | Completed | Results on NCT | Academic publication only | Results unreported |
|---|---|---|---|---|
Pirfenidone | 54 | 18 (33.3%) | 20 (37.0%) | 16 (29.6%) |
Hydroxychloroquine | 154 | 38 (24.7%) | 59 (38.3%) | 57 (37.0%) |
Azithromycin | 343 | 78 (22.7%) | 119 (34.7%) | 146 (42.6%) |
Favipiravir | 9 | 1 (11.1%) | 1 (11.1%) | 7 (77.8%) |
Oseltamivir | 101 | 38 (37.6%) | 18 (17.8%) | 45 (44.6%) |
Sarilumab | 18 | 13 (72.2%) | 2 (11.1%) | 3 (16.7%) |
Tocilizumab (atlizumab) | 267 | 125 (46.8%) | 44 (16.5%) | 98 (36.7%) |
Remdesivir | 1 | 0 (0.0%) | 0 (0.0%) | 1 (100%) |
Leflunomide | 20 | 5 (25.0%) | 4 (20.0%) | 11 (55.0%) |
Interferon-alpha | 1049 | 347 (33.1%) | 301 (28.7%) | 401 (38.2%) |
Lopinavir/ritonavir | 927 | 287 (31.0%) | 265 (28.6%) | 375 (40.5%) |
Darunavir/ritonavir | 216 | 73 (33.8%) | 66 (30.6%) | 77 (35.6%) |
Baloxavir marboxil | 5 | 2 (40.0%) | 0 (0.0%) | 3 (60.0%) |
Umifenovir | 2 | 0 (0.0%) | 2 (100.0%) | 0 (0.0%) |
Interferon-beta | 285 | 84 (29.5%) | 84 (29.5%) | 117 (41.1) |
Sofosbuvir | 176 | 36 (20.5%) | 42 (23.9%) | 98 (55.7%) |
Nitazoxanide | 48 | 11 (22.9%) | 12 (25.0%) | 25 (52.1%) |
APN01 (ACE2 analogue) | 1 | 0 (0.0%) | 1 (100.0%) | 0 (0.0%) |
Ivermectin | 78 | 16 (20.5%) | 26 (33.3%) | 36 (46.2%) |
Totals | 3754 | 1172 (31.2%) | 1066 (28.4%) | 1516 (40.4%) |